Curcumin suppresses invasiveness and vasculogenic mimicry of squamous cell carcinoma of the larynx through the inhibition of JAK-2/STAT-3 signaling pathway

American Journal of Cancer Research

Volumn 5, Issue 1, 2015, Pages 278-288

  Hu, An ^a   Huang, Jing Juan ^b   Jin, Xiao Jie ^c   Li, Ji Ping ^c   Tang, Yuan Jia ^b   Huang, Xin Fang ^b   Cui, Hui Juan ^b   Xu, Wei Hua ^a   Sun, Guang Bin ^d  

^a Department of Otolaryngology Gong li Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Curcumin; JAK 2 ; laryngeal squamous cell carcinoma; STAT 3 signaling pathway; Vasculogenic mimicry

Indexed keywords

CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEP 2 CELL LINE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INTRACELLULAR SIGNALING; LARYNX SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULOGENIC MIMICRY; WESTERN BLOTTING;

EID: 85043218169     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ramroth H, Schoeps A, Rudolph E, Dyckhoff G, Plinkert P, Lippert B, Feist K, Delank KW, Scheuermann K, Baier G, Ott I, Chenouda S, Becher H and Dietz A. Factors predicting survival after diagnosis of laryngeal cancer. Oral Oncol 2011; 47: 1154-1158.
3. Boyle P and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
4. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
5. Folberg R, Hendrix MJ and Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-381.
6. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC and Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 2001; 98: 8018-8023.
7. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJ. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004; 190: 899-909.
8. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV and Hendrix MJ. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 2012; 181: 1115-1125.
9. Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R and Chi J. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 2014; 13: 207.
10. Yao L, Sun B, Zhao X, Gu Q, Dong X, Zheng Y, Sun J, Cheng R, Qi H and An J. Overexpression of Wnt5a promotes angiogenesis in NSCLC. Biomed Res Int 2014; 2014: 832562.
11. Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, Dong X and Chi J. Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol 2013; 108: 414-419.
12. Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J, Sun T, Wang J, Sun R and Liu Y. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol 2014; 133: 575-583.
13. Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S and Lacal PM. Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of alphavbeta5 integrin. Int J Cancer 2014; [Epub ahead of print].
14. Wang W, Lin P, Han C, Cai W, Zhao X and Sun B. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res 2010; 29: 60.
15. Lee CH, Wu YT, Hsieh HC, Yu Y, Yu AL and Chang WW. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells. Biochimie 2014; 104: 117-126.
16. Chiablaem K, Lirdprapamongkol K, Keeratichamroen S, Surarit R and Svasti J. Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res 2014; 34: 1857-1864.
17. Kim I, Moon SO, Park SK, Chae SW and Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001; 89: 477-479.
18. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999; 428: 305-327.
19. Huang MT, Ma W, Lu YP, Chang RL, Fisher C, Manchand PS, Newmark HL and Conney AH. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis 1995; 16: 2493-2497.
20. Singh RP, Dhanalakshmi S, Agarwal C and Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005; 24: 1188-1202.
21. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S and Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222-1232.
22. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM and Dimmeler S. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 2002; 91: 837-844.
23. Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S and Sozen S. Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells. Oncol Lett 2014; 7: 755-763.
24. Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G and Sausville EA. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res 2003; 63: 2812-2819.
25. Samsonov A, Zenser N, Zhang F, Zhang H, Fetter J and Malkov D. Tagging of genomic STAT3 and STAT1 with fluorescent proteins and insertion of a luciferase reporter in the cyclin D1 gene provides a modified A549 cell line to screen for selective STAT3 inhibitors. PLoS One 2013; 8: e68391.
26. Costa-Pereira AP, Bonito NA and Seckl MJ. Dysregulation of janus kinases and signal transducers and activators of transcription in cancer. Am J Cancer Res 2011; 1: 806-816.
27. Park JW, Zhao L and Cheng SY. Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor beta in xenograft models. Am J Cancer Res 2013; 3: 302-311.
28. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM and Sethi G. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 2013; 1835: 46-60.
29. Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J and McKay CJ. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg 2013; 17: 887-898.
30. Marino F, Orecchia V, Regis G, Musteanu M, Tassone B, Jon C, Forni M, Calautti E, Chiarle R, Eferl R and Poli V. STAT3beta controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. Am J Cancer Res 2014; 4: 484-494.
31. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749.
32. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE and Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629.
33. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD and Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277.
34. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB and Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-1287.
35. Heidemann J, Binion DG, Domschke W and Kucharzik T. Antiangiogenic therapy in human gastrointestinal malignancies. Gut 2006; 55: 1497-1511.
36. de Gramont A, Tournigand C, Andre T, Larsen AK and Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 2007; 34: S37-40.